Technical Analysis for GBT - Global Blood Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
48.07 | 0.10% | 0.05 |
GBT closed up 0.1 percent on Monday, August 19, 2019, on 54 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical GBT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.10% | |
| Oversold Stochastic | Weakness | 0.10% | |
| Down 3 Days in a Row | Weakness | 2.98% | |
| Oversold Stochastic | Weakness | 2.98% | |
| Oversold Stochastic | Weakness | -0.15% | |
| 200 DMA Resistance | Bearish | -0.68% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.68% | |
| Lower Bollinger Band Walk | Weakness | -0.68% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Medicine Biopharmaceutical Medical Specialties Blood Sickle Cell Disease Hereditary Angioedema Angioedema Hemoglobin Hemoglobins
Medicine Biopharmaceutical Medical Specialties Blood Sickle Cell Disease Hereditary Angioedema Angioedema Hemoglobin Hemoglobins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GBT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 64.94 |
| 52 Week Low | 30.15 |
| Average Volume | 979,425 |
| 200-Day Moving Average | 50.3902 |
| 50-Day Moving Average | 54.6546 |
| 20-Day Moving Average | 51.857 |
| 10-Day Moving Average | 48.612 |
| Average True Range | 2.1529 |
| ADX | 32.48 |
| +DI | 13.336 |
| -DI | 26.5648 |
| Chandelier Exit (Long, 3 ATRs ) | 52.0413 |
| Chandelier Exit (Short, 3 ATRs ) | 52.9087 |
| Upper Bollinger Band | 59.2204 |
| Lower Bollinger Band | 44.4936 |
| Percent B (%b) | 0.24 |
| BandWidth | 28.398866 |
| MACD Line | -2.2826 |
| MACD Signal Line | -1.9599 |
| MACD Histogram | -0.3227 |
| Fundamentals | Value |
|---|---|
| Market Cap | 2.1 Billion |
| Num Shares | 43.7 Million |
| EPS | -2.46 |
| Price-to-Earnings (P/E) Ratio | -19.54 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.19 |
| PEG Ratio | -0.38 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.73 | ||||
| Resistance 3 (R3) | 50.71 | 49.82 | 50.28 | ||
| Resistance 2 (R2) | 49.82 | 49.14 | 49.82 | 50.13 | |
| Resistance 1 (R1) | 48.94 | 48.72 | 49.38 | 48.96 | 49.99 |
| Pivot Point | 48.05 | 48.05 | 48.27 | 48.05 | 48.05 |
| Support 1 (S1) | 47.17 | 47.37 | 47.61 | 47.19 | 46.15 |
| Support 2 (S2) | 46.28 | 46.95 | 46.28 | 46.01 | |
| Support 3 (S3) | 45.40 | 46.28 | 45.86 | ||
| Support 4 (S4) | 45.42 |
